Profile of elotuzumab and its potential in the treatment of multiple myeloma [0.03%]
elotuzumab的特性及其在多发性骨髓瘤治疗中的应用前景
Yi-Chang Liu,Susann Szmania,Frits van Rhee
Yi-Chang Liu
Although the introduction of novel drugs has improved outcome significantly in multiple myeloma (MM), many patients still eventually relapse. Monoclonal antibodies (mAbs) targeting MM-related antigens can complement currently available ther...
Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future [0.03%]
弥漫性大B细胞淋巴瘤的治疗策略：过去、现在和未来
Rajni Sinha,Loretta Nastoupil,Christopher R Flowers
Rajni Sinha
Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the Western world. DLBCL is a clinically, biologically, and pathologically heterogeneous entity with biologically distinct subtypes that have different expecte...